Research use only ✓ COA GLP-2 Tirz

Incretin Analogs

GLP-2 Tirz Tirzepatide · GLP-2 T · LY3298176

Name: GLP-2 Tirz
Brand: Clean Peptide
SKU: CP-TIRZEPATID
Price: 51.09 USD
Availability: InStock

CAS 2023788-19-2 BATCH 202604TR20

GLP-2 T (GLP-2 Tirz, GLP2-T, GLP 2T) is tirzepatide (LY3298176), Eli Lilly's dual agonist of the GIP and GLP-1 receptors. This GLP-2 T research peptide is lyophilised tirzepatide in 20 mg and 30 mg vials, each size with its own lot certificate. What is tirzepatide? Tirzepatide is a 39-residue synthetic peptide that Eli Lilly built on the sequence of GIP (glucose-dependent insulinotropic polypeptide). One molecule activates two receptors: the GIP receptor (GIPR) and the GLP-1 receptor (GLP1R). Lilly's pharmacology work describes it as "imbalanced": at the exposures used in trials it engages the GIP receptor more than the GLP-1 receptor, and at the GLP-1 receptor it favours cAMP signalling over β-arrestin recruitment. Two Aib residues protect it from enzymatic cleavage, and a C20 fatty diacid on lysine 20 binds albumin, giving an elimination half-life of about five days.

Mass

Clear

Quantity

−30% applied

Order within 15h 46m · ships TueCutoff 3:00 PM ET (12:00 PM PT)
Arrives Thu, Oct 29 – Tue, Nov 3Free standard shipping on orders over $100
Free shipment protectionLost, stolen, or damaged? We replace it, on us.
Overnight and 2-day optionsPick your speed at checkout
We acceptSecure 256-bit checkout

Verified test results

Every batch, independently verified.

Each batch is analyzed by an independent third-party laboratory before it ships. This is the released report for the size selected above, exactly as the lab issued it.

HYTE Research DivisionIndependent third-party laboratory

Certificate of analysis

99.89%

Purity by HPLC

Lot: 202604TR20
Tested: Apr 15, 2026
Labeled: 20mg
Measured: 21.23mg

5× tested

Full QC panel

5 passed

Identity

HPLC-DAD · spec GLP-2-TR

TirzepatidePass

Purity

HPLC-DAD · spec >99% by HPLC

99.89%Pass

Quantity

HPLC assay · spec 20mg

21.23mgPass

Endotoxins

LAL ELISA · limit ≤ 0.5 EU/mL

0.199 EU/mLPass

Sterility

Pour Plate · spec No Growth

No GrowthPass

Every size on record

Open any size’s signed certificate. Your order ships with the report for the size you buy.

GLP-2 Tirz 20mg

Selected

LOT 202604TR20

99.89%

HPLC purity · meets spec

Labeled: 20mg
Measured: 21.23mg
Identity: Tirzepatide
Sterility: No Growth
Endotoxin: 0.199 EU/mL
Tested: Apr 15, 2026

5 assays passed · HYTE Research Division

GLP-2 Tirz 30mg

Selected

LOT ACE-6725667

99.32%

HPLC purity

Labeled: 30mg
Identity: Confirmed
Tested: Aug 24, 2026

Accurate Test Labs, ISO/IEC 17025 accredited

What is tirzepatide?

Tirzepatide is a 39-residue synthetic peptide that Eli Lilly built on the sequence of GIP (glucose-dependent insulinotropic polypeptide). One molecule activates two receptors: the GIP receptor (GIPR) and the GLP-1 receptor (GLP1R). Lilly’s pharmacology work describes it as “imbalanced”: at the exposures used in trials it engages the GIP receptor more than the GLP-1 receptor, and at the GLP-1 receptor it favours cAMP signalling over β-arrestin recruitment. Two Aib residues protect it from enzymatic cleavage, and a C20 fatty diacid on lysine 20 binds albumin, giving an elimination half-life of about five days.

It sits between the two other incretin molecules we stock: semaglutide acts on one receptor (GLP-1R), tirzepatide on two, and retatrutide adds a third (the glucagon receptor). See retatrutide vs tirzepatide.

Why “GLP-2 Tirz” and “GLP-2 T”?

“GLP-2” here is a shop label for “two receptors”, not a scientific name. Tirzepatide is not a GLP-2 analogue: GLP-2 is a separate intestinal hormone with its own receptor, and tirzepatide does not act on it. Research catalogues adopted “GLP-2 T” for tirzepatide the way they use “GLP-3 R” for the triple agonist retatrutide. This product was listed as GLP-2 T and renamed GLP-2 Tirz in October 2026; it is the same material, and the certificates still use the older code names. More in GLP-1 vs GLP-2 vs GLP-3: what the names mean.

Tirzepatide identity

Names	Tirzepatide, LY3298176, GLP-2 T, GLP-2 Tirz, GLP2-T, GLP 2T, tirz; brand names Mounjaro and Zepbound (Eli Lilly)
Sequence	`Y-Aib-EGTFTSDYSI-Aib-LDKIAQ-K*-AFVQWLIAGGPSSGAPPPS-NH2`
Modifications	Aib at positions 2 and 13; Lys20 acylated with a C20 fatty diacid (1,20-eicosanedioic acid) via γGlu and two AEEA linkers; C-terminal amide
Length	39 residues
Molecular formula	C₂₂₅H₃₄₈N₄₈O₆₈
Molecular weight	4813.53 Da (FDA label)
CAS number	2023788-19-2
PubChem CID	156588324
Receptor targets	GIPR and GLP1R (dual agonist)
This product	Lyophilised powder; sizes and stock in the selector above

Sources: the Mounjaro label on DailyMed, the FDA substance registry (GSRS), KEGG and PubChem.

Certificates for the current lots

Each size is filled from its own lot and tested separately, so the certificates come from different laboratories: HYTE Research Division for the 20 mg lot and Accurate Test Labs for the 30 mg lot. The table lists what each one measured:

Size	Lot	Laboratory	Analysed	HPLC purity	Measured content	Identity
20mg	202604TR20	HYTE Research Division	15 Apr 2026	99.89%	21.23mg	Tirzepatide (spec GLP-2-TR)
30mg	ACE-6725667	Accurate Test Labs	24 Aug 2026	99.32%		Confirmed

Transcribed from the certificate issued for each size on sale today. The certificate names the material as GLP-2-TR / GLP-2T. Open the signed certificate for any size under Verified test results above. Every GLP-2 Tirz COA, lot by lot

Tirzepatide price

Price per vial and per milligram, read live from the store:

Size	List price	Price today	Per mg	Availability
20mg	~~$72.99~~	$51.09	$2.55	In stock
30mg	~~$89.99~~	$62.99	$2.10	Out of stock

Read from the store when this page loads, the same prices the GLP-2 Tirz product page shows.

Published research on tirzepatide

Tirzepatide has one of the largest clinical programmes of any peptide: the SURPASS trials in type 2 diabetes and the SURMOUNT trials in obesity, all Lilly-sponsored. Each link goes to the PubMed record.

Discovery to proof of concept (2018). In vitro signalling at both receptors, mouse studies and phase 1 studies in 142 people whose pharmacokinetics supported once-weekly administration. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Coskun T, et al. Molecular Metabolism, 2018.
Receptor pharmacology (2020). At clinical exposures tirzepatide engaged GIPR more than GLP-1R, mimicked native GIP at GIPR and was biased toward cAMP at GLP-1R. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. Willard FS, et al. JCI Insight, 2020.
Phase 2 in type 2 diabetes (2018). A 26-week trial in 318 adults against placebo and dulaglutide; gastrointestinal events were the most common adverse events and were dose-related. Frias JP, et al. Lancet, 2018.
SURPASS-2, against semaglutide (2021). A 40-week open-label trial in 1,879 adults with type 2 diabetes on metformin; HbA1c was the primary end point. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Frías JP, et al. NEJM, 2021.
SURMOUNT-1 (2022). A 72-week placebo-controlled trial in 2,539 adults with obesity or overweight without diabetes, with body-weight change as the primary end point. Tirzepatide Once Weekly for the Treatment of Obesity. Jastreboff AM, et al. NEJM, 2022.
SURMOUNT-OSA (2024). Two 52-week trials in obstructive sleep apnoea with obesity, measuring the apnoea-hypopnoea index. Malhotra A, et al. NEJM, 2024.
SURMOUNT-5, against semaglutide (2025). A 72-week open-label head-to-head trial in 751 adults with obesity without type 2 diabetes. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. Aronne LJ, et al. NEJM, 2025.
SURPASS-CVOT (2025). A cardiovascular outcomes trial in 13,299 adults with type 2 diabetes and atherosclerotic disease, against dulaglutide; it met its non-inferiority margin but not superiority. Nicholls SJ, et al. NEJM, 2025.

Tirzepatide is also the comparator in later trials, including retatrutide’s TRIUMPH-5 (NCT06662383), still running as of October 2026.

Regulatory status

Tirzepatide is an FDA-approved drug, sold by Eli Lilly as Mounjaro (approved 13 May 2022, for type 2 diabetes) and Zepbound (approved 8 November 2023, for chronic weight management, and later for obstructive sleep apnoea in adults with obesity). Mounjaro prescribing information, DailyMed. Clean Peptide’s GLP-2 Tirz is a laboratory reference material, not Lilly’s product, and is not for human or veterinary use.

Related research

GLP-3 Reta (retatrutide) and Survodutide, with their own certificates.
Retatrutide vs tirzepatide and tirzepatide vs semaglutide.
Retatrutide price, with tirzepatide and survodutide prices for comparison.
All incretin analogues.

Technical specification

What is on file, and how it is handled

Every figure below is transcribed from the paperwork for this compound.

Material

Compound: GLP-2 Tirz (Tirzepatide)
Class: Dual GIP / GLP-1 receptor agonist (acylated peptide)
Form: Lyophilised powder
Sizes: 20mg, 30mg
Sequence: Y-Aib-EGTFTSDYSI-Aib-LDKIAQ-K(C20 diacid-γGlu-2xAEEA)-AFVQWLIAGGPSSGAPPPS-NH2
Formula: C225H348N48O68
CAS: 2023788-19-2
Mol. weight: 4813.53 Da
Residues: 39

Verification

Identity: Confirmed on the certificate of analysis
Purity: ≥ 99.89% by HPLC
Batch: 202604TR20
Documentation: Per-batch certificate of analysis

Handling

Storage: Store at −20 °C, protected from light
Intended use: In-vitro laboratory research only

Compound data on PubChem

QuestionsGLP-2 Tirz: frequently asked

What is GLP-2 Tirz?+

GLP-2 Tirz is our name for tirzepatide (LY3298176), Eli Lilly’s 39-residue dual agonist of the GIP and GLP-1 receptors. It was listed as GLP-2 T before October 2026; the material is the same.

Is tirzepatide a GLP-2 agonist?+

No. “GLP-2” in the product name is a catalogue label for a two-receptor agonist. GLP-2 is a separate intestinal hormone, and tirzepatide does not act on its receptor. It acts on the GIP and GLP-1 receptors.

What is the tirzepatide molecular weight?+

4813.53 Da according to the FDA label, for C225H348N48O68. The CAS number is 2023788-19-2 and the PubChem CID is 156588324.

What is the difference between tirzepatide and retatrutide?+

Both are Eli Lilly peptides built on the GIP backbone with a C20 fatty diacid. Tirzepatide activates two receptors (GIPR and GLP-1R); retatrutide activates those two plus the glucagon receptor. Tirzepatide is FDA-approved; retatrutide is still investigational.

Is tirzepatide FDA-approved?+

Yes, as Eli Lilly’s Mounjaro (May 2022, type 2 diabetes) and Zepbound (November 2023, chronic weight management). Clean Peptide’s GLP-2 Tirz is a laboratory reference material, not Lilly’s product.

What do the GLP-2 Tirz certificates show?+

Each size has its own certificate, listed on this page with lot number, laboratory, test date, HPLC purity, measured content where reported, and identity. The 20 mg lot was tested by HYTE Research Division and the 30 mg lot by Accurate Test Labs.

Shop all products